266 related articles for article (PubMed ID: 27199065)
1. Heavy Metals, Cardiovascular Disease, and the Unexpected Benefits of Chelation Therapy.
Lamas GA; Navas-Acien A; Mark DB; Lee KL
J Am Coll Cardiol; 2016 May; 67(20):2411-2418. PubMed ID: 27199065
[TBL] [Abstract][Full Text] [Related]
2. Potential Role of Metal Chelation to Prevent the Cardiovascular Complications of Diabetes.
Calderon Moreno R; Navas-Acien A; Escolar E; Nathan DM; Newman J; Schmedtje JF; Diaz D; Lamas GA; Fonseca V
J Clin Endocrinol Metab; 2019 Jul; 104(7):2931-2941. PubMed ID: 30869793
[TBL] [Abstract][Full Text] [Related]
3. Enhanced vasculotoxic metal excretion in post-myocardial infarction patients following a single edetate disodium-based infusion.
Arenas IA; Navas-Acien A; Ergui I; Lamas GA
Environ Res; 2017 Oct; 158():443-449. PubMed ID: 28689036
[TBL] [Abstract][Full Text] [Related]
4. EDTA Chelation Therapy to Reduce Cardiovascular Events in Persons with Diabetes.
Ouyang P; Gottlieb SH; Culotta VL; Navas-Acien A
Curr Cardiol Rep; 2015 Nov; 17(11):96. PubMed ID: 26364188
[TBL] [Abstract][Full Text] [Related]
5. Chelation therapy to prevent diabetes-associated cardiovascular events.
Diaz D; Fonseca V; Aude YW; Lamas GA
Curr Opin Endocrinol Diabetes Obes; 2018 Aug; 25(4):258-266. PubMed ID: 29846236
[TBL] [Abstract][Full Text] [Related]
6. Baseline characteristics including blood and urine metal levels in the Trial to Assess Chelation Therapy 2 (TACT2).
Navas-Acien A; Santella RM; Joubert BR; Huang Z; Lokhnygina Y; Ujueta F; Gurvich I; LoIacono NJ; Ravalli F; Ward CD; Jarrett JM; Salazar AL; Boineau R; Jones TLZ; Mark DB; Newman JD; Nathan DM; Anstrom KJ; Lamas GA
Am Heart J; 2024 Jul; 273():72-82. PubMed ID: 38621575
[TBL] [Abstract][Full Text] [Related]
7. Chronic Toxic Metal Exposure and Cardiovascular Disease: Mechanisms of Risk and Emerging Role of Chelation Therapy.
Aneni EC; Escolar E; Lamas GA
Curr Atheroscler Rep; 2016 Dec; 18(12):81. PubMed ID: 27822681
[TBL] [Abstract][Full Text] [Related]
8. Edetate Disodium-Based Treatment for Secondary Prevention in Post-Myocardial Infarction Patients.
Lamas GA; Issa OM
Curr Cardiol Rep; 2016 Feb; 18(2):20. PubMed ID: 26797807
[TBL] [Abstract][Full Text] [Related]
9. Possible differential benefits of edetate disodium in post-myocardial infarction patients with diabetes treated with different hypoglycemic strategies in the Trial to Assess Chelation Therapy (TACT).
Escolar E; Ujueta F; Kim H; Mark DB; Boineau R; Nahin RL; Goertz C; Lee KL; Anstrom KJ; Lamas GA
J Diabetes Complications; 2020 Aug; 34(8):107616. PubMed ID: 32446881
[TBL] [Abstract][Full Text] [Related]
10. The trial to assess chelation therapy 2 (TACT2): Rationale and design.
Lamas GA; Anstrom KJ; Navas-Acien A; Boineau R; Kim H; Rosenberg Y; Stylianou M; Jones TLZ; Joubert BR; Santella RM; Escolar E; Aude YW; Fonseca V; Elliott T; Lewis EF; Farkouh ME; Nathan DM; Mon AC; Gosnell L; Newman JD; Mark DB;
Am Heart J; 2022 Oct; 252():1-11. PubMed ID: 35598636
[TBL] [Abstract][Full Text] [Related]
11. Chelation Therapy as a Cardiovascular Therapeutic Strategy: the Rationale and the Data in Review.
Mathew RO; Schulman-Marcus J; Nichols EL; Newman JD; Bangalore S; Farkouh M; Sidhu MS
Cardiovasc Drugs Ther; 2017 Dec; 31(5-6):619-625. PubMed ID: 29129003
[TBL] [Abstract][Full Text] [Related]
12. The effect of EDTA-based chelation on patients with diabetes and peripheral artery disease in the Trial to Assess Chelation Therapy (TACT).
Ujueta F; Arenas IA; Escolar E; Diaz D; Boineau R; Mark DB; Golden P; Lindblad L; Kim H; Lee KL; Lamas GA
J Diabetes Complications; 2019 Jul; 33(7):490-494. PubMed ID: 31101487
[TBL] [Abstract][Full Text] [Related]
13. Chelation therapy in cardiovascular disease: an update.
Sultan S; Murarka S; Jahangir A; Mookadam F; Tajik AJ; Jahangir A
Expert Rev Clin Pharmacol; 2017 Aug; 10(8):843-854. PubMed ID: 28597699
[TBL] [Abstract][Full Text] [Related]
14. Heavy Metal Toxicity in Chronic Renal Failure and Cardiovascular Disease: Possible Role for Chelation Therapy.
Glicklich D; Shin CT; Frishman WH
Cardiol Rev; 2020; 28(6):312-318. PubMed ID: 32040019
[TBL] [Abstract][Full Text] [Related]
15. Metal pollutants and cardiovascular disease: mechanisms and consequences of exposure.
Solenkova NV; Newman JD; Berger JS; Thurston G; Hochman JS; Lamas GA
Am Heart J; 2014 Dec; 168(6):812-22. PubMed ID: 25458643
[TBL] [Abstract][Full Text] [Related]
16. Low-Level Metal Contamination and Chelation in Cardiovascular Disease-A Ripe Area for Toxicology Research.
Ujueta F; Navas-Acien A; Mann KK; Prashad R; Lamas GA
Toxicol Sci; 2021 May; 181(2):135-147. PubMed ID: 33662137
[TBL] [Abstract][Full Text] [Related]
17. Chelation therapy and cardiovascular disease: connecting scientific silos to benefit cardiac patients.
Peguero JG; Arenas I; Lamas GA
Trends Cardiovasc Med; 2014 Aug; 24(6):232-40. PubMed ID: 25106084
[TBL] [Abstract][Full Text] [Related]
18. Metal chelation therapy in rheumathoid arthritis: a case report. Successful management of rheumathoid arthritis by metal chelation therapy.
Bamonti F; Fulgenzi A; Novembrino C; Ferrero ME
Biometals; 2011 Dec; 24(6):1093-8. PubMed ID: 21655943
[TBL] [Abstract][Full Text] [Related]
19. Urinary Metal Levels after Repeated Edetate Disodium Infusions: Preliminary Findings.
Alam ZH; Ujueta F; Arenas IA; Nigra AE; Navas-Acien A; Lamas GA
Int J Environ Res Public Health; 2020 Jun; 17(13):. PubMed ID: 32610666
[TBL] [Abstract][Full Text] [Related]
20. Chelation therapy to treat atherosclerosis, particularly in diabetes: is it time to reconsider?
Lamas GA; Ergui I
Expert Rev Cardiovasc Ther; 2016 Aug; 14(8):927-38. PubMed ID: 27149141
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]